Attached files
file | filename |
---|---|
EX-99.1 - INVESTOR PRESENTATION, DATED MARCH 2021 - AIkido Pharma Inc. | ea137036ex99-1_aikidopharm.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K |
CURRENT REPORT |
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Date of Report (Date of earliest event reported): March 5, 2021 |
AIKIDO PHARMA INC. |
(Exact name of registrant as specified in its charter) |
Delaware | 000-05576 | 52-0849320 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
One Rockefeller Plaza, 11th Floor, New York, NY | 10020 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (703) 992-9325 | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.0001 par value | AIKI | The Nasdaq Capital Market |
Item 7.01 Regulation FD Disclosure
On March 9, 2021, AIkido Pharma Inc. (the “Company”) will present at the H.C. Wainwright & Co. Global Life Sciences Conference to be held virtually. The Company will use an investor presentation during the event and a copy of this investor presentation is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The foregoing information (including the exhibit hereto) is being furnished hereunder. Such information (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
99.1 | Investor Presentation, dated March 2021. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AIKIDO PHARMA INC. | ||
By: | /s/ Anthony Hayes | |
Name: Title: |
Anthony Hayes Chief Executive Officer |
Dated: March 5, 2021
2